Electromagnetic actuation System for Samarium Cobalt Eyelid Implants

面神经麻痹（FNP）会导致部分或完全功能失调的眼睑眨眼， 发病率为13 ~ 40例/10万人。最 FNP的身体有害后果是不能眨眼，这是一种称为兔眼症的病症。 OptoEngineering Inc.是一家位于蒙特利尔的创业公司，它开发了一种新技术， 检测非麻痹眼睑中的眨眼并在非麻痹眼睑中产生同步、自然和完整的眨眼。 FNP患者的无功能眼睑麻痹。该系统由三个部分组成，1） 一种基于光学检测和集成软件的非接触式眨眼检测系统， 93%的功能眼睑的眨眼，2）植入眼睑中的眨眼刺激系统，其使用薄的 由100%钐钴制成的稀土磁体盘，并涂有一层聚对二甲苯-C， 确保颗粒粘附性和生物相容性，以及3）电感耦合致动器系统以控制SmCo 磁铁眨眼无功能麻痹眼睑。该公司已成功完成设计， 前两个组件的原型。该公司现在有兴趣开发第三个组件， 感应耦合致动器系统，以控制SmCo磁体作为拟议项目的一部分。的好处 加拿大经济在4年内可以量化，直到全面的实验和临床试验 OptoEngineering的最终目标是将这种新的医疗器械商业化，用于 兔眼所提出的系统为FNP患者提供了易用性、帮助和支持。

Facial Nerve Paralysis (FNP) will result in partial or complete dysfunctional eyelid blinking, which accounts for 50% of all cases in Bell's Palsy with incidence rate of 13 to 40 cases per 100,000 people annually. The most physically detrimental consequence of FNP is the inability to blink, a condition known as lagophthalmos. OptoEngineering Inc. is a Montreal based startup company that has developed a novel technology capable of detecting blinking in the non-paralyzed eyelid and producing a synchronous, natural and complete blink in the non-functioning paralyzed eyelid for patients suffering with FNP. The system consists of three components, 1) a non-contact blink detection system based on optical detection and integrated software that can detect about 93% of the blink of the functioning eyelid, 2) a blink stimulation system implanted in the eyelid that uses a thin disk of rare earth magnets that is made of 100% samarium cobalt and coated with a layer of parylene-C to ensure particle adhesion and biocompatibility, and 3) an inductive coupled actuator system to control the SmCo magnet to blink non-functioning paralyzed eyelid. The company has successfully completed the design and prototype of the first two components. The company is now interested in developing the third component of the inductive coupled actuator system to control the SmCo magnet as part of the proposed project. The benefits to the Canadian economy are quantifiable within 4 years until the full experimentation and clinical trials have been completed as OptoEngineering ultimate objective is to commercialize this new medical device for use in lagophthalmos. The proposed system offers ease of use and assistance and support to the patients with FNP.